Invisible Sentinel Inc., a life sciences company that develops rapid diagnostics for the detection of foodborne pathogens, announced that Bruce Peacock was elected to Invisible Sentinel's Board of Directors as an independent director.
Mr. Peacock brings over 35 years of experience as a life sciences executive to Invisible Sentinel, and has held executive leadership roles with some of the most successful life science companies to have emerged from the region.
Mr. Peacock began his career in biotechnology in 1982 as CFO of Centocor. He was instrumental as part of a team that raised over $850 million in debt, equity capital, and alliances. In 1992, Mr. Peacock joined Cephalon, Inc., and as COO, oversaw corporate development, finance, manufacturing operations, and the successful launch of Provigil(R), Cephalon's first proprietary product. He then was CEO of Orthovita (VITA), a Philadelphia based biomaterials company, and followed by serving Adolor (ADLR), a Philadelphia based pharmaceutical company, as CEO.
"Invisible Sentinel is one of the most exciting young companies in the region and I'm excited to be joining them as a director. I look forward to working with management to grow the Company," said Mr. Peacock.
"Bruce is one of the most highly respected life science executives in the business. We are pleased to add him to the Invisible Sentinel Board and his vast experience in corporate finance and operations will be invaluable assets as we grow the Company," said Nick Siciliano , co-founder and COO of Invisible Sentinel.
Since 2006, Mr. Peacock has served as a Venture Partner with SV Life Sciences Advisors, LLC, and also currently serves as the Chief Business Officer at Opthotech, Inc. Mr. Peacock earned a bachelor's degree in Business Administration from Villanova and is a certified public accountant.
About Invisible SentinelBased in Philadelphia at the University City Science Center, Invisible Sentinel develops diagnostic technologies for a safer food supply. The Company's focus is on developing rapid diagnostics that quickly provide accurate information about the presence of harmful pathogens. The first in class patented technology, produced under good manufacturing practices, provides the same data as the USDA reference methods but minimizes the time, reduces the cost, and lowers the overhead associated with conventional diagnostics. The food industry is the first market that the Company is targeting, but its platform technology has the potential to provide valuable tools for additional industries including healthcare, veterinary, biodefense, and environmental testing, where rapid detection of target analytes from unrefined samples is critical. Uniquely designed for easy, practical useon-site and throughout the entire food distribution networkInvisible Sentinel's proprietary diagnostic products promise to create a new standard for rigorous quality control.
About the University City Science CenterThe University City Science Center accelerates technology commercialization, regional economic development, and the market availability of life-enhancing scientific breakthroughs by bringing together innovations, scientists, entrepreneurs, funding, laboratory facilities, and business services. Established in 1963 and headquartered in Philadelphia, PA, the Science Center was the first, and remains the largest, urban research park in the United States. Graduate organizations and current residents of the University City Science Center's Port business incubators have created more than 15,000 jobs that remain in the Greater Philadelphia region today and contribute more than $9 billion to the regional economy annually. For more information about the Science Center, go to www.sciencecenter.org.
Contact: Benjamin Pascal Phone: 215-966-6118Email: firstname.lastname@example.org
SOURCE Invisible Sentinel Inc.